• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic
On December 22, 2021, the United States FDA approved inclisiran, an siRNA targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and statin therapy for low-density lipoprotein cholesterol (LDL-C) reduction in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD).1 Inclisiran has demonstrated ∼50% time-averaged reduction in LDL-C and offers potential in promoting patient adherence as a twice-yearly long-acting injectable.
Source: Journal of Clinical Lipidology - October 31, 2022 Category: Lipidology Authors: Tommy T. Chiou, Kimberly Tomasi, Pam R. Taub, Michael J. Wilkinson Tags: Brief Communication Source Type: research

Ability to Suppress TGF- β-Activated Myofibroblast Differentiation Distinguishes the Anti-pulmonary Fibrosis Efficacy of Two Danshen-Containing Chinese Herbal Medicine Prescriptions
Conclusion: This study suggests that a clinically efficacious cardiovascular Chinese herbal medicine (DLP) can be successfully repurposed to treat a lung disease in pulmonary fibrosis guided by TCM theory. Our comparative study between DLP and DHP demonstrated a critical requirement of suppressing both pro-inflammatory and pro-fibrotic pathways for the treatment of pulmonary fibrosis, supporting that a multi-component prescription capable of “removing both phlegm and blood stasis” will better achieve co-protection of heart and lung in PHD. Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic ...
Source: Frontiers in Pharmacology - April 23, 2019 Category: Drugs & Pharmacology Source Type: research